Enrollment complete in second BPH Phase 3 trial

Patient enrollment is complete in Nymox Pharmaceuticals' (NYMX -0.4%) second re-injection Phase 3 clinical trial evaluating the safety and efficacy on NX-1207 as a treatment of enlarged prostate or benign prostatic hyperplasia (BPH). In the first re-injection study, patients demonstrated a mean symptomatic improvement in the AUA BPH Symptom Score of 7.6 points.

NX-1207 is administered by injection directly into the prostate gland. It is currently being assessed in five Phase 3 trials and one Phase 2 trial.

Comments (1)
  • gebby
    , contributor
    Comments (1995) | Send Message
    Looks like a secondary is coming. Check with your broker. Stock can not be borrowed.
    15 Jul 2014, 11:44 AM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs